<DOC>
	<DOCNO>NCT00082277</DOCNO>
	<brief_summary>The purpose study evaluate safety parameter anastrozole regard potential effect postmenopausal bone loss lipid profile . This trial conduct investigate effect risedronate BMD bone metabolism postmenopausal woman use anastrozole adjuvant therapy hormone-receptor-positive early breast cancer high moderate risk fragility fracture . It also conduct determine effect anastrozole bone mineral density ( BMD ) bone metabolism woman low risk fragility fracture .</brief_summary>
	<brief_title>Anastrozole Biphosphonate Study Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Women define Postmenopausal Histologically proven operable invasive breast cancer Hormonereceptorpositive breast cancer Clinical evidence metastatic disease Bilateral hip fracture bilateral hip prosthesis Receiving receive last 12 month hormonal therapy breast cancer , bisphosphonate therapy , oestrogens Malabsorption syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>hormone-receptor positive , breast cancer</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>risk fracture</keyword>
	<keyword>bone loss</keyword>
</DOC>